How many patients with MS do you have personally under your care:

Which best describes your practice type?

• Academic:
• Private Practice:
• Community Practice:

Does your practice have its own infusion center?

Of your [X] MS patients, how many patients do you currently have on the following treatments:

• Ocrevus
• Kesimpta
• Briumvi

What is your general view of how Briumvi compares with Ocrevus? Select one.

Over the past 6 months, how many NEW to anti-CD20 patients did you start on:

• Ocrevus
• Kesimpta
• Briumvi

Over the next 6 months, how many NEW to anti-CD20 patients do you plan to start on:

• Ocrevus
• Kesimpta
• Briumvi

Of the patients who were on Ocrevus prior to Briumvi coming to market, please indicate the following switch percentages % (Please enter 0-100 for each):

• What % of those have switched from Ocrevus to Briumvi already?
• What % of those have not yet switched but you expect to switch from Ocrevus to Briumvi in the next 2 years?

Of the patients who were on Kesimpta prior to Briumvi coming to market, please indicate the following switch percentages % (Please enter 0-100 for each):

• What % of those have switched from Kesimpta to Briumvi already?
• What % of those have not yet switched but you expect to switch from Kesimpta to Briumvi in the next 2 years?

You mentioned that you have [X] total patients on the three branded ANTI-CD20 drugs today. How many patients TOTAL do you expect to have on the 3 branded ANTI-CD20 drug at the following points in time:

• 6 months from now:
• 1 year from now:
• 2 years from now:
• 5 years from now:

You mentioned that you currently have [X] patients on Briumvi. How many patients TOTAL do you expect to have ON BRIUMVI at the following points in time (please factor all drivers of patient additions and discontinuations including new to anti-CD20 patient starts, switches to and from other anti-CD20s, and patient discontinuations):

• 6 months from now:
• 1 year from now:
• 2 years from now:
• 5 years from now:

Is your ability to prescribe Briumvi gated by the existence of an institutional formulary at the center where you work?

Is Briumvi on formulary yet at your institution?
/Displayed if Q12= Yes/

Approximately how many months ago was it added? Your best estimate is sufficient.
/Displayed if Q13= Yes/

Do you expect Briumvi to eventually be added to your institutional formulary?
/Displayed if Q13= No/

What is your estimate of how many months it will be before Briumvi gets added to your INSTITUTIONAL FORMULARY?
/Displayed if Q13= No/

How does the ease or difficulty of getting Briumvi approved by insurance compare with that for Ocrevus? Select one.

• Briumvi is much easier than Ocrevus: 
• Briumvi is a little easier than Ocrevus: 
• They are about the same:
• Briumvi is a little more difficult than Ocrevus: 
• Briumvi is a lot more difficult than Ocrevus:

How when you look at your total economics for prescribing Briumvi vs Ocrevus at the personal level for you, how would you compare how PROFITABLE IT IS FOR YOU to prescribe Briumvi vs Ocrevus?

• A lot more profitable: 
• A little more profitable: 
• Similarly Profitable: 
• A little less profitable: 
• Much less profitable: 
• Not sure:

From your first-hand clinical experience, does Briumvi offer superior, inferior, or similar infusion tolerability compared with Ocrevus?

• Greatly superior infusion tolerability: 
• Somewhat superior infusion tolerability: 
• Similar infusion tolerability: 
• Somewhat inferior infusion tolerability: 
• Greatly inferior infusion tolerability: 
• Not enough first-hand experience yet:

Please comment on any meaningful differences in EFFICACY (including performance on crap gap) that you perceive between Ocrevus & Briumvi?

Of your patients who will be newly prescribed an anti-CD20 drug for the first time and who end up deciding between BRIUMVI and Ocrevus and ultimately choosing Briumvi, how would you allocate the percentage (%) that have each one of the 5 possibilities below as their PRIMARY REASON FOR PREFERRING BRIUMVI (sum of the 5 options to 100%):

• Superior perceived efficacy (including better crap gap):
• Superior perceived tolerability:
• Superior perceived safety (incl not having a breast cancer warning):
• 1-hour infusion time advantage:
• Other:

In earlier questions, you indicated that you started [X] patients on Briumvi over the past 6 months and intend to start [X] patients over the next 6 months. Please allocate 100 points to the following possible reasons for expecting increased or decreased usage of Briumvi?

• Improving (or worsening) insurance coverage:
• Improving (or worsening) preference for shorter infusion time:
• Improving (or worsening) preference for Briumvi's TOLERABILITY:
• Improving (or worsening) preference for Briumvi's EFFICACY profile:
• Improving (or worsening) preference for Briumvi's PERFORMANCE ON CRAP GAP:
• Improving (or worsening) preference for Briumvi's SAFETY profile:
• Easier infusion scheduling from shorter infusion time:
• Increasing (or worsening) doctor preference for the economics from BRIUMVI'S shorter infusion time and reimbursement dynamics:
• Other:

How familiar are you with the recently approved drug called Ocrevus Zunovo, the Subcutaneous Formulation of Ocrevus and the details of how the drug is administered, where 1 is not at all familiar and 10 is extremely familiar?

How much do you expect to utilize Ocrevus Zunovo in your practice in the year ahead, where 0 = not at all and 10 = extremely broadly?
/Displayed if Q23 = 7 or above/

Of the patients who you would have envisioned putting on Briumvi OVER THE NEXT YEAR prior to Ocrevus Zunovo coming to market, what percent (%) of those patients will you now instead put them on Ocrevus Zunovo instead now that the option is available?
/Displayed if Q23 = 7 or above/